1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Melanoma - Pipeline Review, 2015

Melanoma - Pipeline Review, 2015

  • October 2015
  • -
  • Global Data
  • -
  • 86 pages

Melanoma - Pipeline Review, 2015

Summary

GlobalData's Medical Devices sector report, “Melanoma - Pipeline Review, 2015" provides an overview of Melanoma diagnostic tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Melanoma diagnostic tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Melanoma diagnostic tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Melanoma diagnostic tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Melanoma diagnostic tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table Of Contents

Melanoma - Pipeline Review, 2015
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Melanoma Overview 9
3 Products under Development 10
3.1 Melanoma - Pipeline Products by Stage of Development 10
3.2 Melanoma - Pipeline Products by Territory 11
3.3 Melanoma - Pipeline Products by Regulatory Path 12
3.4 Melanoma - Pipeline Products by Estimated Approval Date 13
3.5 Melanoma - Ongoing Clinical Trials 14
4 Melanoma - Pipeline Products under Development by Companies 15
4.1 Melanoma Companies - Pipeline Products by Stage of Development 15
4.2 Melanoma - Pipeline Products by Stage of Development 17
5 Melanoma Companies and Product Overview 19
5.1 Abbott Diagnostics Company Overview 19
5.1.1 Abbott Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 19
5.2 Adaptive Biotechnologies Corporation Company Overview 23
5.2.1 Adaptive Biotechnologies Corporation Pipeline Products and Ongoing Clinical Trials Overview 23
5.3 Advanced Cell Diagnostics, Inc. Company Overview 25
5.3.1 Advanced Cell Diagnostics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 25
5.4 Agilent Technologies, Inc. Company Overview 26
5.4.1 Agilent Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 26
5.5 BioMarker Strategies, LLC Company Overview 28
5.5.1 BioMarker Strategies, LLC Pipeline Products and Ongoing Clinical Trials Overview 28
5.6 Biosceptre (Aust) Pty Ltd Company Overview 30
5.6.1 Biosceptre (Aust) Pty Ltd Pipeline Products and Ongoing Clinical Trials Overview 30
5.7 Boston University Company Overview 31
5.7.1 Boston University Pipeline Products and Ongoing Clinical Trials Overview 31
5.8 Ceres Nanosciences, Inc. Company Overview 32
5.8.1 Ceres Nanosciences, Inc. Pipeline Products and Ongoing Clinical Trials Overview 32
5.9 Dana-Farber Cancer Institute, Inc. Company Overview 33
5.9.1 Dana-Farber Cancer Institute, Inc. Pipeline Products and Ongoing Clinical Trials Overview 33
5.10 Digna Biotech, S.L. Company Overview 34
5.10.1 Digna Biotech, S.L. Pipeline Products and Ongoing Clinical Trials Overview 34
5.11 Exosomics Siena SpA Company Overview 35
5.11.1 Exosomics Siena SpA Pipeline Products and Ongoing Clinical Trials Overview 35
5.12 Genomic Health, Inc. Company Overview 36
5.12.1 Genomic Health, Inc. Pipeline Products and Ongoing Clinical Trials Overview 36
5.13 Hospital Universitario Cruces Company Overview 38
5.13.1 Hospital Universitario Cruces Pipeline Products and Ongoing Clinical Trials Overview 38
5.14 HTG Molecular Diagnostics, Inc. Company Overview 39
5.14.1 HTG Molecular Diagnostics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 39
5.15 ImmunID Technologies Company Overview 41
5.15.1 ImmunID Technologies Pipeline Products and Ongoing Clinical Trials Overview 41
5.16 InterGenetics Incorporated Company Overview 45
5.16.1 InterGenetics Incorporated Pipeline Products and Ongoing Clinical Trials Overview 45
5.17 IV Diagnostics, Inc. Company Overview 46
5.17.1 IV Diagnostics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 46
5.18 Louisville Bioscience, Inc. Company Overview 47
5.18.1 Louisville Bioscience, Inc. Pipeline Products and Ongoing Clinical Trials Overview 47
5.19 MDNA Life Sciences, Inc. Company Overview 48
5.19.1 MDNA Life Sciences, Inc. Pipeline Products and Ongoing Clinical Trials Overview 48
5.20 Melanovus Oncology, Inc. Company Overview 49
5.20.1 Melanovus Oncology, Inc. Pipeline Products and Ongoing Clinical Trials Overview 49
5.21 MolecularMD, Corp. Company Overview 50
5.21.1 MolecularMD, Corp. Pipeline Products and Ongoing Clinical Trials Overview 50
5.22 Myriad Genetics, Inc. Company Overview 51
5.22.1 Myriad Genetics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 51
5.23 Orion Genomics LLC Company Overview 53
5.23.1 Orion Genomics LLC Pipeline Products and Ongoing Clinical Trials Overview 53
5.24 Oryzon Genomics S.A. Company Overview 54
5.24.1 Oryzon Genomics S.A. Pipeline Products and Ongoing Clinical Trials Overview 54
5.25 Pacific Edge Limited Company Overview 56
5.25.1 Pacific Edge Limited Pipeline Products and Ongoing Clinical Trials Overview 56
5.26 Qiagen N.V. Company Overview 58
5.26.1 Qiagen N.V. Pipeline Products and Ongoing Clinical Trials Overview 58
5.27 Roche Diagnostics International Ltd. Company Overview 60
5.27.1 Roche Diagnostics International Ltd. Pipeline Products and Ongoing Clinical Trials Overview 60
5.28 Rosetta Genomics, Ltd. Company Overview 64
5.28.1 Rosetta Genomics, Ltd. Pipeline Products and Ongoing Clinical Trials Overview 64
5.29 Sividon Diagnostics GmbH Company Overview 66
5.29.1 Sividon Diagnostics GmbH Pipeline Products and Ongoing Clinical Trials Overview 66
5.30 SomaLogic, Inc. Company Overview 67
5.30.1 SomaLogic, Inc. Pipeline Products and Ongoing Clinical Trials Overview 67
5.31 The Johns Hopkins University Company Overview 68
5.31.1 The Johns Hopkins University Pipeline Products and Ongoing Clinical Trials Overview 68
5.32 University of California, San Francisco Company Overview 70
5.32.1 University of California, San Francisco Pipeline Products and Ongoing Clinical Trials Overview 70
5.33 University of Colorado Company Overview 72
5.33.1 University of Colorado Pipeline Products and Ongoing Clinical Trials Overview 72
5.34 University of Louisville Company Overview 73
5.34.1 University of Louisville Pipeline Products and Ongoing Clinical Trials Overview 73
5.35 Zymera, Inc Company Overview 74
5.35.1 Zymera, Inc Pipeline Products and Ongoing Clinical Trials Overview 74
6 Melanoma- Recent Developments 75
7 Appendix 83
7.1 Methodology 83
7.2 About GlobalData 85
7.3 Contact Us 86
7.4 Disclaimer 86

1.1 List of Tables
Table 1: Melanoma - Pipeline Products by Stage of Development 10
Table 2: Melanoma - Pipeline Products by Territory 11
Table 3: Melanoma - Pipeline Products by Regulatory Path 12
Table 4: Melanoma - Pipeline Products by Estimated Approval Date 13
Table 5: Melanoma - Ongoing Clinical Trials 14
Table 6: Melanoma Companies - Pipeline Products by Stage of Development 15
Table 7: Melanoma - Pipeline Products by Stage of Development 17
Table 8: Abbott Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 19
Table 9: MAGE-A3 Companion Skin Cancer Assay - Product Status 20
Table 10: MAGE-A3 Companion Skin Cancer Assay - Product Description 20
Table 11: MAGE-A3 Skin Cancer Assay - Product Status 21
Table 12: MAGE-A3 Skin Cancer Assay - Product Description 21
Table 13: MYB Companion Diagnostic Assay - Melanoma - Product Status 22
Table 14: MYB Companion Diagnostic Assay - Melanoma - Product Description 22
Table 15: Adaptive Biotechnologies Corporation Pipeline Products and Ongoing Clinical Trials Overview 23
Table 16: Companion Diagnostic Test - Melanoma Cancer - Product Status 24
Table 17: Companion Diagnostic Test - Melanoma Cancer - Product Description 24
Table 18: Advanced Cell Diagnostics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 25
Table 19: RNAscope MELA - Product Status 25
Table 20: RNAscope MELA - Product Description 25
Table 21: Agilent Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 26
Table 22: MK-3475 Companion Diagnostic Test - Product Status 27
Table 23: MK-3475 Companion Diagnostic Test - Product Description 27
Table 24: BioMarker Strategies, LLC Pipeline Products and Ongoing Clinical Trials Overview 28
Table 25: Ex Vivo Biomarker Test - Melanoma - Product Status 28
Table 26: Ex Vivo Biomarker Test - Melanoma - Product Description 28
Table 27: PathMAP - Product Status 29
Table 28: PathMAP - Product Description 29
Table 29: Biosceptre (Aust) Pty Ltd Pipeline Products and Ongoing Clinical Trials Overview 30
Table 30: Skin Cancer IHC Diagnostic Test - Product Status 30
Table 31: Skin Cancer IHC Diagnostic Test - Product Description 30
Table 32: Boston University Pipeline Products and Ongoing Clinical Trials Overview 31
Table 33: Microfluidic Chip - Melanoma - Product Status 31
Table 34: Microfluidic Chip - Melanoma - Product Description 31
Table 35: Ceres Nanosciences, Inc. Pipeline Products and Ongoing Clinical Trials Overview 32
Table 36: Melanoma Skin Patch Sweat Test - Product Status 32
Table 37: Melanoma Skin Patch Sweat Test - Product Description 32
Table 38: Dana-Farber Cancer Institute, Inc. Pipeline Products and Ongoing Clinical Trials Overview 33
Table 39: Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Status 33
Table 40: Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Description 33
Table 41: Digna Biotech, S.L. Pipeline Products and Ongoing Clinical Trials Overview 34
Table 42: Melanoma Test - Product Status 34
Table 43: Melanoma Test - Product Description 34
Table 44: Exosomics Siena SpA Pipeline Products and Ongoing Clinical Trials Overview 35
Table 45: EXOTEST Melanoma - Product Status 35
Table 46: EXOTEST Melanoma - Product Description 35
Table 47: Genomic Health, Inc. Pipeline Products and Ongoing Clinical Trials Overview 36
Table 48: Prognostic Test - Melanoma - Product Status 37
Table 49: Prognostic Test - Melanoma - Product Description 37
Table 50: Hospital Universitario Cruces Pipeline Products and Ongoing Clinical Trials Overview 38
Table 51: Diagnostic Assay - Melanoma - Product Status 38
Table 52: Diagnostic Assay - Melanoma - Product Description 38
Table 53: HTG Molecular Diagnostics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 39
Table 54: Diagnostic Test - Melanoma - Product Status 40
Table 55: Diagnostic Test - Melanoma - Product Description 40
Table 56: ImmunID Technologies Pipeline Products and Ongoing Clinical Trials Overview 41
Table 57: ImmunTraCkeR - Metastatic Melanoma - Product Status 42
Table 58: ImmunTraCkeR - Metastatic Melanoma - Product Description 42
Table 59: ImmunID Technologies - Ongoing Clinical Trials Overview 43
Table 60: ImmunTraCkeR - Metastatic Melanoma - Multicenter Clinical Study to Assess the Use of Immune Competence Profiles evaluated by ImmunTracker in Metastatic Melanoma Subjects Treated with an Immune Checkpoint Inhibitor 44
Table 61: InterGenetics Incorporated Pipeline Products and Ongoing Clinical Trials Overview 45
Table 62: OncoVue Skin - Product Status 45
Table 63: OncoVue Skin - Product Description 45
Table 64: IV Diagnostics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 46
Table 65: IVDiagnostics Diagnostic Test - Melanoma - Product Status 46
Table 66: IVDiagnostics Diagnostic Test - Melanoma - Product Description 46
Table 67: Louisville Bioscience, Inc. Pipeline Products and Ongoing Clinical Trials Overview 47
Table 68: Melanoma Remission pT Test - Product Status 47
Table 69: Melanoma Remission pT Test - Product Description 47
Table 70: MDNA Life Sciences, Inc. Pipeline Products and Ongoing Clinical Trials Overview 48
Table 71: Diagnostic Test - Melanoma - Product Status 48
Table 72: Diagnostic Test - Melanoma - Product Description 48
Table 73: Melanovus Oncology, Inc. Pipeline Products and Ongoing Clinical Trials Overview 49
Table 74: Companion Diagnostic Test - Melanoma - Product Status 49
Table 75: Companion Diagnostic Test - Melanoma - Product Description 49
Table 76: MolecularMD, Corp. Pipeline Products and Ongoing Clinical Trials Overview 50
Table 77: Diagnostic Assay - Melanoma - Product Status 50
Table 78: Diagnostic Assay - Melanoma - Product Description 50
Table 79: Myriad Genetics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 51
Table 80: myPath Melanoma - Product Status 52
Table 81: myPath Melanoma - Product Description 52
Table 82: Orion Genomics LLC Pipeline Products and Ongoing Clinical Trials Overview 53
Table 83: Diagnostic Assay - Melanoma - Product Status 53
Table 84: Diagnostic Assay - Melanoma - Product Description 53
Table 85: Oryzon Genomics S.A. Pipeline Products and Ongoing Clinical Trials Overview 54
Table 86: Diagnostic Assay - Melanoma Cancer - Product Status 54
Table 87: Diagnostic Assay - Melanoma Cancer - Product Description 54
Table 88: Prognostic Assay - Melanoma Cancer - Product Status 55
Table 89: Prognostic Assay - Melanoma Cancer - Product Description 55
Table 90: Pacific Edge Limited Pipeline Products and Ongoing Clinical Trials Overview 56
Table 91: Prognostic Assay - Melanoma - Product Status 57
Table 92: Prognostic Assay - Melanoma - Product Description 57
Table 93: Qiagen N.V. Pipeline Products and Ongoing Clinical Trials Overview 58
Table 94: NRAS Assay-Melanoma - Product Status 59
Table 95: NRAS Assay-Melanoma - Product Description 59
Table 96: Roche Diagnostics International Ltd. Pipeline Products and Ongoing Clinical Trials Overview 60
Table 97: ETBR ADC Companion Diagnostic Test - Product Status 61
Table 98: ETBR ADC Companion Diagnostic Test - Product Description 61
Table 99: PDL1+Zelboraf Companion Diagnostic Test - Product Status 62
Table 100: PDL1+Zelboraf Companion Diagnostic Test - Product Description 62
Table 101: Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Status 63
Table 102: Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Description 63
Table 103: Rosetta Genomics, Ltd. Pipeline Products and Ongoing Clinical Trials Overview 64
Table 104: Diagnostic Test - Melanoma - Product Status 65
Table 105: Diagnostic Test - Melanoma - Product Description 65
Table 106: Sividon Diagnostics GmbH Pipeline Products and Ongoing Clinical Trials Overview 66
Table 107: Diagnostic Assay - Melanoma - Product Status 66
Table 108: Diagnostic Assay - Melanoma - Product Description 66
Table 109: SomaLogic, Inc. Pipeline Products and Ongoing Clinical Trials Overview 67
Table 110: Diagnostic Test - Melanoma - Product Status 67
Table 111: Diagnostic Test - Melanoma - Product Description 67
Table 112: The Johns Hopkins University Pipeline Products and Ongoing Clinical Trials Overview 68
Table 113: Biomarker Based Diagnostic Assay - Melanoma - Product Status 68
Table 114: Biomarker Based Diagnostic Assay - Melanoma - Product Description 68
Table 115: Diagnostic Assay - Metastatic Melanoma - Product Status 69
Table 116: Diagnostic Assay - Metastatic Melanoma - Product Description 69
Table 117: University of California, San Francisco Pipeline Products and Ongoing Clinical Trials Overview 70
Table 118: Diagnostic Assay - Uveal Melanoma - Product Status 71
Table 119: Diagnostic Assay - Uveal Melanoma - Product Description 71
Table 120: University of Colorado Pipeline Products and Ongoing Clinical Trials Overview 72
Table 121: Biomarker Test - BRAF Mutations - Product Status 72
Table 122: Biomarker Test - BRAF Mutations - Product Description 72
Table 123: University of Louisville Pipeline Products and Ongoing Clinical Trials Overview 73
Table 124: Melanoma Sentinel Lymph Node Biomarker Test - Product Status 73
Table 125: Melanoma Sentinel Lymph Node Biomarker Test - Product Description 73
Table 126: Zymera, Inc Pipeline Products and Ongoing Clinical Trials Overview 74
Table 127: Prognostic Assay - Melanoma - Product Status 74
Table 128: Prognostic Assay - Melanoma - Product Description 74
Table 129: Glossary 84

1.2 List of Figures
Figure 1: Melanoma - Pipeline Products by Stage of Development 10
Figure 2: Melanoma - Pipeline Products by Territory 11
Figure 3: Melanoma - Pipeline Products by Regulatory Path 12
Figure 4: Melanoma - Pipeline Products by Estimated Approval Date 13
Figure 5: Melanoma - Ongoing Clinical Trials 14

Companies Mentioned
Abbott Diagnostics
Adaptive Biotechnologies Corporation
Advanced Cell Diagnostics, Inc.
Agilent Technologies, Inc.
BioMarker Strategies, LLC
Biosceptre (Aust) Pty Ltd
Boston University
Ceres Nanosciences, Inc.
Dana-Farber Cancer Institute, Inc.
Digna Biot

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
TCR/CAR-T Therapies in Oncology: Analytical Tool

TCR/CAR-T Therapies in Oncology: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...

Tumor Ablation Market by Technology, Mode of Treatment, Application - Global Forecast 2021

Tumor Ablation Market by Technology, Mode of Treatment, Application - Global Forecast 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global tumor ablation market is estimated to register a high CAGR of 12.5% during 2016-2021, and is expected to be valued at ~USD 580.1 million in 2021. Although mature markets (North America and Europe) ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.